PolyPid is a biopharmaceutical company developing long-acting, controlled-release medicines at the site of care, including D-PLEX100 for surgical site infections.
PolyPid operates as a biopharmaceutical company that develops long-acting medicines with controlled release, delivered locally where care is given. Its Kynatrix platform eliminates burst release and transports small molecules, biologics, and peptides, with release durations adjustable from days to weeks.
D-PLEX100 is an incisional prophylactic therapy for preventing surgical site infections, releasing a broad-spectrum antibiotic at the surgical wound directly for 30 days. Regulators granted D-PLEX100 FDA Fast Track, Breakthrough Therapy, and QIDP designations.
D-PLEX100 is a surgical site infection prevention therapy evaluated for preventing abdominal colorectal surgical site infections through localized doxycycline delivery.
